PortViewPortView
Apimeds Pharmaceuticals US, Inc logo

Apimeds Pharmaceuticals US, Inc (APUS) Stock Analysis

AMEXHealthcareBiotechnology

$2.79-21.19%
1-year price historyRange $2.79 – $39.00
52-week range$2.79
$2.76$59.70

What Apimeds Pharmaceuticals US, Inc does

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Key metrics

Market cap
$4.21M
P/E (TTM)
-1.03
EPS (TTM)
$-2.71
Beta
0.15
Dividend yield
0.00%
Revenue / share
$0.00
50-day avg
$6.08
200-day avg
$14.56
52-week high
$59.70
52-week low
$2.76
CEO
Vinod Menon

ETFs linked to APUS

Broad-market and Healthcare sector ETFs an investor holding Apimeds Pharmaceuticals US, Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how APUS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze APUS in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Apimeds Pharmaceuticals US, Inc?
Apimeds Pharmaceuticals US, Inc trades under the ticker APUS on AMEX.
Which exchange is APUS listed on?
APUS is listed on AMEX.
What sector does Apimeds Pharmaceuticals US, Inc operate in?
Apimeds Pharmaceuticals US, Inc is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze APUS in a portfolio?
PortView shows APUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.